Patrys Limited, an Australian company, develops and commercializes antibody technologies for the treatment of cancer. Its lead technology, Deoxymab 3E10, is a DNA damage-repair antibody that inhibits mechanisms of DNA repair in cancer cells. The company is also developing PAT-DX1 and PAT-DX3, antibodies for the treatment of brain cancer, breast cancer, and glioblastoma, and PAT-DX1-NP, which delivers therapeutic payloads to cancer cells. Patrys Limited collaborates with Imagion Biosystems Limited for enhancing brain tumor imaging and diagnosis. The company was founded in 2006 and is headquartered in Melbourne.
Patrys Limited's ticker is PAB
The company's shares trade on the ASX stock exchange
They are based in Melbourne, Australia
There are 11-50 employees working at Patrys Limited
It is https://patrys.com/
Patrys Limited is in the Healthcare sector
Patrys Limited is in the Biotechnology industry
The following five companies are Patrys Limited's industry peers: